Smoking cessation and risk of esophageal cancer by histological type : systematic review and meta-analysis by Qiao-Li, Wang et al.
  
 
 
 
 
 
 
 
 
 
 
 
This is the peer reviewed version of the following article: J Natl 
Cancer Inst. 2017 Dec 1;109(12), which has been published in 
final form at  
 
http://dx.doi.org/10.1093/jnci/djx115 
 
Smoking cessation and risk of esophageal cancer by 
histological type : systematic review and meta-analysis 
 
Qiao-Li, Wang; Shao-Hua, Xie; Wen-Tao, Li; Lagergren, 
Jesper 
 
Access to the published version may require subscription. 
Published with permission from: Oxford University Press 
 
   
1 
 
JNCI 17-0131R1 
Systematic review 
 
Smoking Cessation and Risk of Esophageal Cancer by Histological Type: Systematic Review and 
Meta-analysis 
 
Qiao-Li Wang 1, Shao-Hua Xie 1, Wen-Tao Li 1,2, Jesper Lagergren 1,3 
 
Affiliations:  
1 Upper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska 
Institutet, Karolinska University Hospital, Stockholm, Sweden. 
2 Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, 
Hong Kong SAR, China. 
3 Division of Cancer Studies, King's College London, London, United Kingdom. 
 
Correspondence:   
Dr. Shao-Hua Xie, Upper Gastrointestinal Surgery, Department of Molecular medicine and 
Surgery, Karolinska Institutet, NS 67, 2nd Floor, Stockholm 17176, Sweden, Tel.: +46-8-517-
70917, Fax: +46-8-517-76280, E-mail: shaohua.xie@ki.se 
 
Abbreviations used in this paper:  CI, confidence intervals; RR, risk ratio; ESCC, esophageal 
squamous cell carcinoma; EAC, esophageal adenocarcinoma.   
2 
 
ABSTRACT  
Background: Tobacco smoking strongly increases risk of esophageal squamous cell carcinoma 
and moderately increases risk of esophageal adenocarcinoma. How smoking cessation 
influences esophageal cancer risk across histological subtypes, time latencies, and geographic 
regions is not clear.  
Methods: Studies were systematically searched on Medline, Embase, Web-of-Science, Cochrane 
Library, and ClinicalTrial.gov. Pooled estimates of risk ratios (RRs) were derived using random 
effects model. Cochran’s Q test and I2 statistic were used to detect heterogeneity.  
Results: Among 15,009 studies, 52 fulfilled the inclusion criteria. Using non-smokers as 
reference, risk of esophageal squamous cell carcinoma was lower among former smokers 
(RR=2.05, 95% confidence intervals (CI) 1.71-2.45) than among current smokers (RR=4.18, 95% 
CI 3.42-5.12). Compared with current smokers, a strong risk reduction was evident ≥5 years 
(RR=0.59, 95% CI 0.47-0.75), and became stronger ≥10 years (RR=0.42, 95% CI 0.34-0.51) and 
≥20 years (RR=0.34, 95% CI 0.25-0.47) following smoking cessation. The risk reduction was 
strong in Western populations, while weak in Asian populations. Using non-smokers as 
reference, the risk of esophageal adenocarcinoma was only slightly lower among former 
smokers (RR=1.66, 95% CI 1.48-1.85) than among current smokers (RR=2.34, 95% CI 2.04-2.69). 
The risk of esophageal adenocarcinoma did not show any clear reduction over time after 
smoking cessation, with RR of 0.72 (95% CI 0.52-1.01) ≥20 years after smoking cessation, 
compared with current smokers.  
Conclusions: Smoking cessation time-dependently decreases risk of esophageal squamous cell 
carcinoma, particularly in Western populations, while it has limited influence on the risk of 
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esophageal adenocarcinoma. 
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Esophageal cancer is the 9th most common cancer and the 6th leading cause of cancer 
death globally (1). The overall prognosis is poor (<20% 5-year survival) and has not improved 
much despite intensive research aiming to develop the treatment, which stresses the need for 
preventive actions. Esophageal cancer has two main histological subtypes, squamous cell 
carcinoma (ESCC) and adenocarcinoma (EAC). ESCC accounts for 80% of cases globally and is the 
dominant subtype in Asian countries (2). In many Western countries, however, the incidence of 
EAC has increased rapidly during the last four decades and now exceeds that of ESCC (3, 4). 
Tobacco smoking and heavy alcohol consumption are the main risk factors for ESCC, 
particularly in Western populations (5). Dietary factors, socioeconomic status, exposure to 
environmental carcinogens, and inherited susceptibility may play a stronger role in etiology of 
ESCC in Asian populations compared with Western populations (6-8). The main risk factors for 
EAC are gastroesophageal reflux disease and obesity, while tobacco smoking is only a 
moderately strong risk factor (9-11). However, these studies are base d on Western populations. 
In Asia, on the other hand, the incidence rate of EAC remains low and the etiology of EAC has 
rarely been studied (12).There is a dose-response association between smoking and both 
subtypes of esophageal cancer, and 49% of ESCC cases are estimated to be attributable to 
smoking (13-15). Although one literature review and one pooled analysis of 12 studies indicated 
a decreased risk of esophageal cancer following tobacco smoking cessation (14, 16), it is not 
clear how smoking cessation influences the risk of esophageal cancer across histological 
subtypes, time latencies between cessation and risk reductions, and geographic areas globally. 
Yet, such knowledge should be of great importance for public health and healthcare. Therefore, 
we conducted a systematic review and meta-analysis which, to the best of our knowledge, is the 
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first study aiming to clarify the role of smoking cessation in relation to the risk of esophageal 
cancer with separate assessments of the main histological subtypes, time latencies, and 
geographic regions. 
 
 
Methods   
Search strategy and selection criteria  
This systematic literature review and meta-analysis was performed in accordance with 
the PRISMA statement and MOOSE guidelines (17, 18). The search strategy was discussed and a 
final search string was agreed upon by all authors. A systematic search was conducted on 
MEDLINE, Embase, Web-of-Science and Cochrane Library databases (up to March 30, 2016) for 
studies reporting data on the association between tobacco smoking cessation and the risk of 
esophageal cancer. For the search, we used a combination of three themes of Medical Subject 
Headings terms and related extended versions: “smoking or tobacco”, “esophageal or 
oesophageal”, and “cancer, squamous cell carcinoma or adenocarcinoma”. No restrictions in the 
search strategy were used. Reports on ongoing registered clinical trials from the National 
Institute of Health website (http://www.clinicaltrials.gov) were also considered. In addition, we 
reviewed the reference lists of original studies, review articles, systematic reports, and the two 
monographs on “Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines” and “Tobacco 
Smoking and Involuntary Smoking” by the International Agency for Research on Cancer (IARC) 
to identify further studies of potential interest (19, 20). The search strategy is presented in more 
detail in the Supplementary Methods. 
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Studies fulfilling the following criteria were considered for inclusion in the systematic 
review: 1) smoking status was ascertained and data were presented as odds ratios (OR), risk 
ratios (RR), hazard ratios (HR), or in another format from which the relative risk could be 
estimated; 2) case-control studies, cohort studies, intervention studies, and clinical trials; and 3) 
original and independent studies with full text. Language restriction was implemented only at 
the end of the search when only studies published in English were eligible. In the case of 
multiple reports on the same study population, only the most recent or most informative report 
with the longest follow-up was considered. We followed a detailed study protocol that was 
completed before initiation of the search for eligible studies.  
One reviewer (Q.L. Wang) conducted the initial search and removed obviously irrelevant 
articles by screening the titles and abstracts according to the selection criteria. The final 
decision of articles selected for the review was made by all authors. We contacted the 
investigators for relevant data if their studies were potentially eligible for this study.  
 
Data extraction and quality assessment 
Identified studies were independently assessed by two authors (Q.L. Wang and W.T. Li) 
and any discrepancies were resolved by joint review of reports to reach consensus, or 
determined by a third author (S.H. Xie). The following information was collected from the 
eligible studies into an electronic database: author names, year of publication, geographic 
origin, number of participants, number and type of case patients (incident or prevalent), 
participants’ characteristics (ethnic origin, mean age, and sex), histological subtype of 
esophageal cancer (squamous cell carcinoma or adenocarcinoma), method of ascertainment of 
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case patients, smoking status (non-, former, or current, and years since smoking cessation), 
control for potential confounding factors (by matching or statistical analysis), and statistical 
analysis. For case-control studies, we collected information on participation rates and how 
control subjects were recruited. For cohort studies and clinical trials, information of 
representativeness of the study participants and the completeness, period, and duration of 
follow-up were recorded.  
The methodological quality of the studies was assessed in terms of selection bias, 
information bias, and bias from confounding. We quantitatively scored the study quality 
according to the nine-item Newcastle-Ottawa Scale (21), which includes assessment of the 
generalizability of the study population, selection of control subjects or non-exposed cohort 
members, exposure, definition of control subjects or participants at the start of the cohort, 
adjustment for relevant confounders, outcome, response rate or completeness of follow-up, 
and rate of loss to follow-up or drop-outs. An additional item was added to the scale, i.e. if 
smoking was investigated as the main exposure (1 point) or as a confounding variable only (0 
point) (22). The methodological quality assessment could provide a score from 0 to 10 on the 
final scale, where higher scores represent better quality.  
 
Statistical analysis 
Tobacco smoking status (current, former, or non-smoker) and time latencies of smoking 
cessation were analyzed in relation to the risk of ESCC and EAC separately. In most included 
studies, current smokers were defined as those who smoked at the time of recruitment into the 
study or those who stopped smoking less than one or two years before recruitment. Former 
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smokers were defined as those who quit smoking one or two years before inclusion, although 
two studies used five years as the boundary for current and former smokers (23, 24). In the 
analyses of latency time after smoking cessation, some studies used current smokers as the 
reference group, while other studies used non-smokers. Therefore, in the meta-analysis, the 
reference groups were all uniformed to current smokers for an easier understanding of smoking 
cessation, using method suggested by Hamling et al (25). We categorized smoking cessation 
latency into five groups: non- smokers, <5 years, 5-9 years, 10-20 years, or >20 years. Some 
studies reported more than one category of duration for the first 5 years or over 20 years after 
smoking cessation, e.g. multiple categories of <2 years and3-5 years for the first 5 years, or 20-
29 years and >30 years for the over 20 years (26-29). In such cases, we combined these 
categories into a single one, i.e. <5 years or >20 years, according to the meta-analysis approach 
by pooling the estimates for these more than two  categorizes into one estimates of the risk 
ratio (30). 
RR was used as the measure of association in the meta-analysis. For some studies, HR 
and OR were used as proxies of RR, which was justified by the low incidence of esophageal 
cancer (30). To take heterogeneity into account, we used random effects model (Der-Simonian 
and Laird’s method) to compute the pooled RRs and we also calculated their 95% confidence 
intervals (CIs) (31). 
Statistical heterogeneity across studies was assessed by the Cochran’s Q test (a P-value 
<0.10 being considered as statistically significant for conservativeness of the test) (32), and I2 
statistic which describes the proportion of the total variation in study estimates that is due to 
heterogeneity rather than by chance (33). An I2 value of <25% indicated low heterogeneity, 25-
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50% moderate, and >50% is suggestive of high heterogeneity (34). We conducted stratified 
analyses by study design (case-control or cohort study), publication year (≤1999, 2000-2009, or 
≥2010), geographic origin of the study (North America, Europe, Oceania, Asia, or South 
America), gender (men, women or unspecified), response rate (≥80%, <80%, or unknown), 
smoking exposure (main exposure or confounder), tobacco type (cigarettes or unspecified), 
study quality (low with score <7 or high with score ≥7 ), potential confounding factors adjusted 
for (alcohol use, dietary factors, socio-economy, place of residence, body mass index, or 
gastroesophageal reflux). For case-control studies, we stratified analyses by study design 
(population-based or hospital-based), cases recruitment (incident, prevalent or unknown), and 
source of control subjects (neighborhood or unrelated). For cohort studies, we stratified for 
study design (population-based or hospital-based), follow-up time (<10 years or ≥10 years), and 
assessment of outcomes (record linkage or self-reported).  
Publication bias was evaluated using Begg’s and Egger’s tests, as well as visual inspection 
of the funnel plots (35, 36). In addition, exploratory meta-regression was performed to examine 
potential sources of heterogeneity using the same covariates as in the stratified analysis, where 
P-values of <.10 were regarded statistically significant. We used sensitivity analyses by removing 
one study at a time to examine the robustness of the pooled RRs. The statistical analyses were 
conducted using the Comprehensive Meta-Analysis program version 3.3 (Biostat, Englewood, 
NJ, USA). All statistical tests were two-sided. 
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Results  
Literature search and study characteristics  
The search identified 15,009 studies. Among these, 52 studies fulfilled the inclusion 
criteria and were enrolled to this meta-analysis (Figure 1)(9, 23, 24, 26-29, 37-81). Of the 52 
studies, 41 and 23 studies contained smoking data in relation to risk of ESCC and EAC, 
respectively. Most studies were case-control studies (n=44) including a total of 11,965 
esophageal cancer cases and 47,817 control subjects, and the remaining (n=8) were cohort 
studies with 1,185 new esophageal cancer cases among 1,045,947 cohort members. No 
randomized clinical trials met the inclusion criteria. Most studies were conducted in Europe 
(n=22), the United States (n=10), and Mainland China or Taiwan (n=7), while the remaining 
studies were conducted in Japan (n=3), Brazil (n=3), Uruguay (n=3), Argentina (n=1), Australia 
(n=1), Czech Republic (n=1), and Serbia (n=1). Two studies from the United Kingdom were 
performed on the same study population, but analyzed the two eligible histological types of 
esophageal cancer in separate studies (45, 49). Two studies from Uruguay had partly 
overlapping study periods (52, 53). Some overlap of research centers was possible in three 
studies from Italy or Switzerland (44, 47, 48), and two studies from Taiwan were partly 
overlapping (57, 75). Supplementary Tables 1 and 2 provide an overview of characteristics of 
the included case-control studies and cohort studies, respectively. 
 
Quality assessment 
A detailed study quality assessment is shown in Supplementary Tables 3-5. In brief, of all 
41 studies examining ESCC, 22 (53.7%) had a high quality score (≥7) and 19 (46.3%) had a lower 
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quality score (<7). Of all 23 studies analyzing EAC, 17 (73.9%) had a high quality score (≥7) and 6 
(26.1%) had a lower quality score (<7). Thirty (57.7%) of all 52 studies reported different 
categories of years after smoking cessation, including 18 analyzing ESCC and 12 analyzing EAC. 
Among these, one study analyzing EAC did not report more categories than <26 years of 
smoking cessation, and was therefore not included in the further analysis (23). Detailed results 
by duration since smoking cessation in the original studies are presented in Supplementary 
Table 6. Eighteen (34.6%) studies reported sex-specific associations. All but 10 (19.2%) studies 
examined tobacco smoking as the main exposure. Among the 44 case-control studies, 16 were 
population-based and 31 analyzed incident cancer cases. Among the cohort studies, all but one 
identified case patients via record linkages and the longest follow-up was 22.2 years. 
Adjustment for age and sex was made in all studies except for one (76). Adjustments for other 
potential confounding factors in the included studies are shown in Supplementary Table 3.  
 
Smoking cessation and esophageal squamous cell carcinoma 
In an analysis of the 41 studies assessing ESCC, former smokers had an RR of 2.05 (95% 
CI 1.71-2.45, Figure 2), and current smokers had an RR of 4.18 (95% CI 3.42-5.12, 
Supplementary Figure 1), compared to non-smokers. There was a dose-response association 
between smoking cessation latency time and risk of ESCC (Figure 3A). Compared to current 
smokers, those who had quit smoking <5 years ago had an RR of 0.96 (95% CI 0.73-1.25), and 
those who had quit smoking 5-9 years, 10-20 years, and >20 years ago had RRs of 0.59 (95% CI 
0.47-0.75), 0.42 (95% CI 0.34-0.51), and 0.34 (95% CI 0.25-0.47), respectively (Figure 3A, 
Supplementary Figure 2). The RR for those who quit smoking >20 years ago was similar to that 
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of non-smokers with an RR of 0.22 (95% CI 0.18-0.28). In a sensitivity analysis restricted to 
studies that reported RRs of all smoking cessation latency categories, the results were similar to 
those of the overall analyses (Supplementary Table 7). The meta-analysis revealed substantial 
heterogeneity across studies for RRs in former smokers (I2=69.6%, P<.001) and current smokers 
(I2=85.0%, P<.001).  
The results from the stratified analyses are shown in Table 1. All RRs in former smokers 
were lower than RRs in current smokers in each stratum for ESCC, although heterogeneity 
(I2>50%) was found in most strata. The difference in RR between former smokers and current 
smokers was most pronounced in studies from North America and Europe, while it was not 
evident in Asian studies. Among former smokers, women had lower RRs of ESCC than men. High 
quality studies (score ≥7) generated higher RRs of ESCC among current smokers and lower RRs 
among former smokers, compared with low quality studies (score <7). The results remained 
stable after adjustment for alcohol use and dietary factors. In hospital-based case-control 
studies, the RRs among both former and current smokers were slightly higher compared to 
population-based studies (Table 1).   
The meta-regression showed that sex and study quality could explain 11.0% (P=.08) and 
13.6% (P=.06) of the heterogeneity in former smokers, respectively (data not shown). The 
continent where the study was conducted and source of controls (neighborhood-based or 
unrelated) could explain 9.1% (P=.02) and 19.1% (P=.01) of the heterogeneity in current 
smokers, respectively. The sensitivity analyses excluding one study at a time showed no 
substantial changes (Supplementary Figure 3 and 4). 
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Smoking cessation and esophageal adenocarcinoma 
In an analysis of all 23 studies, former smokers had an RR of 1.66 (95% CI 1.48-1.85, 
Figure 4) and current smokers had an RR of 2.34 (95% CI 2.04-2.69, Supplementary Figure 5), 
compared to non-smokers. No substantial heterogeneity of the RRs was revealed for former 
smokers (I2=11.6%, P=.30) or current smokers (I2=26.0%, P=.13). Studies from North America 
(n=10) showed the highest RR among former smokers (RR=1.87, 95% CI 1.62-2.16) and current 
smokers (RR=2.52, 95% CI 2.14-2.96), compared to studies from other continents 
(Supplementary Table 8).  
Compared to current smokers, smoking cessation <5 years ago was associated with an 
RR of 0.81 (95% CI 0.52-1.26), 5-9 years with an RR of 0.87(95% CI 0.58-1.30), 10-20 years with 
an RR of 0.95(95% CI 0.78-1.15) and >20 years ago with an RR of 0.72 (95% CI 0.52-1.01) (Figure 
3B, Supplementary Figure 6).  
 
Publication bias  
No publication bias was detected by visual inspection of the funnel plot or by the Begg’s 
and Egger’s test (Supplementary Figure 7). For ESCC, P-values for former smokers using Begg’s 
and Egger’s test were .17 and .19, respectively. The corresponding P-values for current smokers 
were .09 and .20, respectively. Similarly, no publication bias was found for EAC. The P-values for 
former smokers using Begg’s and Egger’s test were .71 and .63, respectively. The corresponding 
P-values for current smokers were .81 and .33, respectively.  
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Discussion  
This study indicates a strongly decreased risk of ESCC in former smokers compared to 
current smokers, and a clear decline in risk of ESCC already within 5 years of smoking cessation, 
which further decreased with each longer latency period of smoking cessation until after 20 
years, when the risk was similar to that of non-smokers. North American populations seem to 
benefit most from smoking cessation, while Asian populations benefitted the least. There was 
only a small difference in the risk of EAC comparing former and current smokers, and a slightly 
decreased risk of EAC was suggested only among those who had stopped smoking over 20 years 
ago. The observed associations of the risk of ESCC or EAC in current or former smokers persisted 
across subgroups stratified by participants´ characteristics and study design.  
This meta-analysis has several main strengths, including the extensive search strategy 
which should have identified all relevant publications globally. It includes a large number of 
studies and participants, which provides good statistical power for robust subgroup analyses, 
including separate analyses of the main histologic types of esophageal cancer and various 
lengths of smoking cessation periods. There are also limitations; heterogeneity was found 
across studies investigating the risk of ESCC for former and current smokers. This might have 
resulted from the large number of included studies, differences in design, population, and 
quality of the studies, as well as differences in participants’ characteristics. To reduce the 
influence of heterogeneity, random effects model was used. All stratified analyses showed 
decreased RRs among former smokers compared with current smokers. In analyses restricted to 
higher study quality studies, the decrease in RR was greater between current and former 
smokers, indicating the robustness of the findings. The restriction of studies to those published 
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in the English language with full text might have resulted in the exclusion of some small or low 
quality studies. However, the results were unlikely affected by any such exclusion since no 
publication bias was detected. Finally, biases of observational studies cannot be avoided, but 
the results from cohort studies revealed similar results as those from case-control studies, 
which indicate robustness. Moreover, the risk reductions seen after smoking cessation are 
biologically plausible.  
To the best of our knowledge, this is the first systematic review and meta-analysis 
estimating the influence of smoking cessation on the risk of esophageal cancer by histological 
type. Yet, the decreased risk of ESCC among former smokers compared to current smokers is 
consistent with the results of a meta-analysis of 15 Japanese studies, showing an RR of 
esophageal cancer 3.73 (95% CI 2.16-6.43) in current smokers and 2.21 (95% CI 1.60-3.06) in 
former smokers (82). Although the histologic type of cancer was not provided in that study, the 
vast majority of patients with esophageal cancer in Japan have ESCC. Regarding EAC, our results 
are similar to a meta-analysis that included studies published before January 2010, implying an 
RR of esophageal and gastric cardia adenocarcinoma combined of 2.32 (95% CI 1.96-2.75) in 
current smokers and 1.62 (95% CI 1.40-1.87) in former smokers (83). However, due to the 
limited statistical power, separate analysis of EAC (excluding cardia cancer) was not possible in 
that study (83). A pooled analysis of 12 studies suggested benefits of smoking cessation for EAC 
after 10 years (odds ratio 0.71, 95% CI 0.56-0.89) (14). However, the risk of EAC following 
smoking cessation of 10-20 years or more than 20 years was not assessed in that study (14). The 
present meta-analysis showed that any benefit from smoking cessation became evident only 
more than 20 years after smoking cessation, which is in agreement with opinions from two 
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literature review articles (16, 84).  
It is interesting to note that smoking cessation seems to have a stronger influence on 
ESSC risk in Western populations than in Asian populations. The incidence rate of ESCC is 
highest in Asian countries globally, with an estimated 80% of all global ESCC cases occurring in 
Asia, and China alone contributed to more than half of these cases(85). Despite the much 
higher prevalence of tobacco smoking in men than women in Asian populations (e.g. 25.5 times 
higher in men than women in China), the sex difference in the incidence rate of ESCC is less 
marked (e.g. 2.8 times higher in men than women in China) (86, 87). Thus, the high risk of ESCC 
in Asian populations is likely to be attributable to other risk factors ,e.g. dietary factors 
(including hot food and beverage, red and processed meat, low vegetables and fruit, etc.) 
tobacco smoke pollution, household air pollution, and other sources of polycyclic aromatic 
hydrocarbons, and genetic factors (88-94). The high baseline ESCC risk posed by risk factors 
other than tobacco might have neutralized the risk reduction related to smoking cessation in 
Asian populations. Furthermore, a large proportion of Asian studies did not adjust for 
confounders, e.g. alcohol consumption, which might have led to an overestimation of the risk of 
ESCC in former smokers in the study.  
In conclusion, this comprehensive systematic review and meta-analysis of 52 studies 
from different regions globally suggests that smoking cessation is associated with a rapid and 
strong reduction in the risk of ESCC. The benefits of smoking cessation on ESCC were stronger in 
Western populations than in Asian populations. Any reduction of EAC risk following smoking 
cessation is limited and slow. The preventive effects of smoking cessation on esophageal cancer 
shown in this study can help guide future health policy and clinical practice. 
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Figure Legends: 
Figure 1: Flow chart of study selection. ESCC= esophageal squamous cell carcinoma; EAC= 
esophageal adenocarcinoma. 
Figure 2: Forest plot of risk ratio of esophageal squamous cell carcinoma among former smokers 
with non-smokers as reference, stratified by study design. The diamonds represent the effect 
sizes for the studies combined, the squares represent the effect sizes of individual studies and 
the weights given to the studies, and the error bars represent the corresponding 95% 
confidence intervals. CI=confidence interval. 
Figure 3: Risk ratio of esophageal squamous cell carcinoma and adenocarcinoma by duration 
since smoking cessation, using current smokers as reference. A) effect sizes for esophageal 
squamous cell carcinoma; B) effect sizes for esophageal adenocarcinoma. Error bars=95% 
confidence interval.  
Figure 4: Forest plot of risk ratio of esophageal adenocarcinoma among former smokers with 
non-smokers as reference, stratified by study design. The diamonds represent the effect sizes 
for the studies combined, the squares represent the effect sizes of individual studies and the 
weights given to the studies, and the error bars represent the corresponding 95% confidence 
intervals. CI=confidence interval. 
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Supplementary Methods 
Search Strategies  
Medline 
1. (esophagus or gastrointestinal tract).sh. or esophageal.tw. or oesophageal.tw. or esophagus.tw. or 
oesophagus.tw. or upper digestive.tw. or upper aerodigestive.tw. or upper gastrointestin.tw. 
2. (neoplasms or carcinoma or carcinoma, squamous cell or adenocarcinoma).sh. or tumour*.ab. or tumor*.ab. 
or malignan*.ab. or neoplas*.ab. or cancer*.ab. or carcinoma*.ab. 
3. esophageal neoplasms.sh. 
4. (smoking or smoking cessation or tobacco or "tobacco use cessation").sh. or tobacco*.tw. or smok*.tw. or 
cigarette*.tw. or risk factor*.tw. or risk factors.sh. or protective factor.sh. or risk assessment.sh. or 
protective factor*.tw. or risk assessment*.tw. 
5. #1 AND #2 OR #3  
6. #4 AND #5  
Embase 
1. 'esophageal' OR 'esophagus' OR 'oesophageal' OR 'oesophagus' OR 'upper gastrointestinal' OR 'upper 
aerodigestive' OR 'upper digestive' 
2. 'neoplasm'/exp OR 'cancer'/exp OR 'carcinoma'/exp OR 'squamous cell carcinoma'/exp OR 
'adenocarcinoma'/exp OR 'tumour'/exp OR 'tumor'/exp OR 'malignancy' OR 'neoplasia'/exp 
3. 'smoke'/exp OR 'smoking'/exp OR 'smokeless' OR 'smoking cessation'/exp OR 'tobacco'/exp OR 'tobacco 
use cessation'/exp OR 'tobacco use disorder'/exp OR 'tobacco dependence'/exp OR 'smoking dependence' 
OR 'nicotine'/exp OR 'nicotine dependence'/exp OR 'cigarette'/exp 
4. #1 AND #2 AND #3 
5. #4 AND [embase]/lim NOT [medline]/lim 
Web of Science 
1. TOPIC: (esophageal) OR TOPIC: (esophagus) OR TOPIC: (oesophageal) OR TOPIC: (oesophagus) OR 
TOPIC: (upper gastrointestinal) OR TOPIC: (upper aerodigestive) OR TOPIC: (upper digestive) 
2. TOPIC: (neoplasm) OR TOPIC: (cancer) OR TOPIC: (carcinoma) OR TOPIC: (squamous cell carcinoma) 
OR TOPIC: (adenocarcinoma) OR TOPIC: (upper aerodigestive) OR TOPIC: (upper digestive) OR TOPIC: 
(tumour) OR TOPIC: (tumor) OR TOPIC: (malignancy) OR TOPIC: (neoplasia)  
3. TOPIC: (smoke) OR TOPIC: (smoking) OR TOPIC: (smokeless) OR TOPIC: (smoking cessation) OR 
TOPIC: (tobacco) OR TOPIC: (tobacco use cessation) OR TOPIC: (tobacco use disorder) OR TOPIC: 
(tobacco dependence) OR TOPIC: (smoking dependence) OR TOPIC: (nicotine dependence) OR TOPIC: 
(cigarette) 
4. #1 AND #2 AND #3 
Cochrane Library 
1. 'esophageal' or 'esophagus' or 'oesophageal' or 'oesophagus' or 'upper gastrointestinal' or 'upper 
aerodigestive' or 'upper digestive' 
2. 'neoplasm' or 'cancer' or 'carcinoma' or 'squamous cell carcinoma' or 'adenocarcinoma' or 'tumour' or 'tumor' 
or 'malignancy' or 'neoplasia' 
3. MeSH descriptor: [Esophageal Neoplasms] 
4. 'smoke' or 'smoking' or 'smokeless' or 'smoking cessation' or 'tobacco' or 'tobacco use cessation' or 'tobacco 
use disorder' or 'tobacco dependence' or 'smoking dependence' or 'nicotine' or 'nicotine dependence' or 
'cigarette' 
5. #1 and #2 or #3 
6. #4 and #5 
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Supplementary Tables  
Supplementary Table 1: Characteristics of included case-control studies for risk ratio of esophageal squamous 
cell carcinoma (ESCC) and adenocarcinoma (EAC)* 
Reference Country  Study period Sex 
Tumor 
histology 
Cases 
(n) 
Controls 
(n) 
Study 
desig
n 
Case 
recruitme
nt 
Smoking 
exposure  
Steevens et al.2010 (1) Netherlands 1986-2002 Both ESCC/EAC 107/145 3962 P incident main 
Pandeya et al.2008 (2) Australia 2002-2005 Both ESCC/EAC 303/367 1580 P prevalent main 
Hashibe et al.2007 (3) Europe 2000-2002 Both ESCC/EAC 192/35 1114 H incident main 
Vioque et al.2008 (4) Spain 1995-1999 Both ESCC 160 455 H  incident main 
De Stefani et al.2005 (5) Uruguay 1996-2003 Both ESCC 200 400 H  incident confounder 
Lagergren et al.2000 (6) Sweden 1995-1997 Both ESCC/EAC 167/189 820 P incident main 
Zambon et al.2000 (7) North Italy 1992-1997 M ESCC 275 593 H  incident main 
Kabat et al.1993 (8) US 1981-1990 M,W ESCC/EAC 214/194 6772 H  incident main 
Gammon et al.1997 (9) US 1993-1995 Both ESCC/EAC 221/293 695 P incident main 
Launoy et al.1997 (10) France 1991-1994 M ESCC 208 399 H   incident main 
Tanaka et al.2010 (11) Japan 2000-2008 Both ESCC 742 820 H   incident main 
Szymanska et al.2011 
(12) 
Brazil 1998 Both ESCC 171 1707 H incident main 
Castelletto et al.1994 (13) Argentina 1986-1989 Both ESCC 131 262 H   incident main 
Bosetti et al.2000 (14) Italy+Swiss 1992-1999 Both ESCC 404 1070 H  incident main 
Lee et al.2005 (15) Taiwan 1996-2003 Both ESCC 513 818 H  incident main 
Venerito et al.2011 (16) Germany 2006-2010 Both ESCC 75 75 H  incident confounder 
Brown et al.1994 (17) US 1986-1989 M ESCC 373 1364 P incident main 
Wang et al.2013 (18) China 2010-2012 Both ESCC 866 952 H  incident confounder 
Lindblad et al.2005 (19) UK 1994-2001 Both ESCC/EAC 140/287 10000 P prevalent main 
Wang et al.2007 (20) China 2004-2006 M ESCC 355 408 P incident main 
Shivappa et al.2015 (21) Iran NA Both ESCC 47 96 H  NA confounder 
Nasrollahzadeh et al.2008 
(22) 
Iran 2003-2007 Both ESCC 300 571 P prevalent main 
Chen et al.2011 (23) China 2004-2010 Both ESCC 150 300 H  prevalent confounder 
Wu et al.2006 (24) Taiwan NA M ESCC 165 255 H prevalent main 
De Stefani et al.1990 (25) Uruguay 1985-1988 M,W,Both ESCC 261 522 H incident main 
Sewram et al.2003 (26) Uruguay 1988-2000 Both ESCC 344 469 H incident confounder 
Vaughan et al.1995 (27) US 1983-1990 Both ESCC/EAC 106/298 724 P prevalent main 
Gallus et al.2001 (28) Italy+Swiss 1984-1999 W ESCC 114 425 H incident main 
Gao et al.2011 (29) China 1997-2005 M ESCC 376 1107 P incident main 
Mota et al.2013 (30) Brazil 1998-2003 Both ESCC 99 223 H  NA main 
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Gledovic et al.2007 (31) Serbia  1998-2002 Both ESCC 102 102 H   incident main 
Morita et al.2003 (32) Japan 1989-1998 M ESCC 88 228 H   prevalent main 
Sharp et al.2001 (33) UK 1993-1996 W ESCC 159 159 P incident main 
Kollarova et al.2013 (34) Czech 2000-2002 Both ESCC/EAC 48/34 200 H   incident main 
Lee et al.2009 (35) Europe 1987-2005 Both ESCC 152 2221 H incident main 
Lee et al.2012 (36) Taiwan 2001-2007 Both ESCC 305 2250 H  incident confounder 
Wu et al.2001 (37) US 1992-1997 Both EAC 222 1356 P prevalent main 
Brown et al.1994 (38) US 1986-1990 M EAC 174 750 P incident main 
Anderson et al.2007 (39) Ireland 2002-2004 Both EAC 227 260 P NA main 
Victora et al.1987 (40) Brazil 1985-1986 M,W,Both ESCC 171 342 H   incident main 
Cheng et al.2000 (41) UK 1993-1996 W EAC 74 74 P prevalent main  
Xu et al.2013 (42) US 2003-2004 Both EAC 218 218 P prevalent confounder 
Bradbury et al.2009 (43) US 1999-2005 Both EAC 313 455 H incident confounder 
De Jonge et al.2006 (44) Netherlands 2003-2005 Both EAC 91 244 H incident main 
*H=hospital-based study; M=men; P=population-based study; W=women. 
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Supplementary Table 2: Characteristics for included cohort studies for risk ratio of esophageal squamous cell 
carcinoma (ESCC) and adenocarcinoma (EAC)* 
Reference Country  
Study 
period 
Sex 
Tumor 
histology 
Baseline 
age 
Cases  
(n) 
Cohort 
memb
ers(n) 
Follow 
-up 
(year) 
Smoking 
exposure  
Outcome 
assessment    
Freedman et al.2007 
(45) 
US 1995-1996 Both ESCC/EAC 63 302 474606 4.6 main Record linkage 
Zendehdel et al.2008 
(46) 
Sweden 1971-1993 M ESCC/EAC 35 366 336381 22.2 main Record linkage 
Ishiguro et al.2009 (47) Japan 1990-1994 M ESCC 40-59 215 44970 11- 14  main Record linkage 
Bodelon et al.2011 (48) US 1993-1998 W ESCC/EAC 50-79 57 161086 11-16 confounder Self-report 
Ramus et al.2012 (49) UK 1996-2003 M,W,
Both 
EAC 64 73 956 3.8 main Record linkage 
Yates et al.2014 (50) UK 1993-1997 Both EAC 67 66 24068 11-15 main Record linkage 
Sikkema et al.2011 (51) Nether-
lands 
2003-2004 Both EAC 61 26 713 4 main Record linkage 
Coleman et al.2012 (52) Ireland 1993-2008 Both EAC 62 80 3167 7.5 main Record linkage 
*M=men; W=women. 
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Supplementary Table 3: Adjusted variables and quality scores of included studies for risk ratio of esophageal 
squamous cell carcinoma (ESCC) and adenocarcinoma (EAC)  
Reference 
Variables adjusted for* NOS-
ESCC 
NOS-
EAC Age Sex Alcohol BMI Reflux Diet Race SES Location 
Case-control studies            
Steevens et al.2010 (1) 1 1 1 1 0 1 0 1 0 9 8 
Pandeya et al.2008 (2) 1 1 1 1 1 0 0 1 1 6 7 
Hashibe et al.2007 (3) 1 1 1 1 0 1 0 1 1 7 7 
Vioque et al.2008 (4) 1 1 1 0 0 1 0 1 1 9 / 
De Stefani et al.2005 
(5) 
1 1 0 0 0 0 0 0 0 8 / 
Lagergren et al.2000 
(6) 
1 1 1 1 1 1 0 1 0 9 9 
Zambon et al.2000 (7) 1 1 1 0 0 0 0 1 1 7 / 
Kabat et al.1993 (8) 1 1 1 0 0 0 1 1 1 6 6 
Gammon et al.1997 (9) 1 1 1 1 0 0 1 1 1 9 9 
Launoy et al.1997 (10) 1 1 1 0 0 0 0 1 1 7 / 
Tanaka et al.2010 (11) 1 1 1 0 0 0 0 0 1 6 / 
Szymanska et al.2011 
(12) 
1 1 1 0 0 1 0 1 1 9 / 
Castelletto et al.1994 
(13) 
1 1 1 0 0 0 0 1 1 7 / 
Bosetti et al.2000 (14) 1 1 1 0 0 0 0 1 1 7 / 
Lee et al.2005 (15) 1 1 1 0 0 1 0 1 1 7 / 
Venerito et al.2011 (16) 1 1 0 0 0 0 0 0 0 4 / 
Brown et al.1994 (17) 1 1 1 0 0 0 0 1 1 8 / 
Wang et al.2013 (18) 1 1 0 0 0 0 0 0 0 4 / 
Lindblad et al.2005 (19) 1 1 1 1 1 0 0 0 0 9 9 
Wang et al.2007 (20) 1 1 0 0 0 0 0 1 1 7 / 
Shivappa et al.2015 
(21) 
1 1 0 0 0 0 0 0 0 3 / 
Nasrollahzadeh et 
al.2008 (22) 
1 1 0 0 0 0 1 1 1 6 / 
Chen et al.2011 (23) 1 1 0 0 0 0 0 0 0 4 / 
Wu et al.2006 (24) 1 1 1 0 0 0 0 1 0 6 / 
De Stefani et al.1990 
(25) 
1 1 0 0 0 0 0 0 0 6 / 
Sewram et al.2003 (26) 1 1 0 0 0 0 0 0 0 6 / 
Vaughan et al.1995 1 1 1 1 0 0 1 1 0 9 8 
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(27) 
Gallus et al.2001 (28) 1 1 1 1 0 1 0 1 1 7 / 
Gao et al.2011 (29) 1 1 0 0 0 0 0 0 1 7 / 
Mota et al.2013 (30) 1 1 0 0 0 0 0 0 1 4 / 
Gledovic et al.2007 (31) 1 1 0 0 0 0 0 0 1 4 / 
Morita et al.2003 (32) 1 1 0 0 0 0 0 0 1 5 / 
Sharp et al.2001 (33) 1 1 0 0 0 1 0 0 0 8 / 
Kollarova et al.2013 
(34) 
1 1 1 1 0 1 0 0 0 6 6 
Lee et al.2009 (35) 1 1 1 0 0 0 0 1 1 6 / 
Lee et al.2012 (36) 1 1 0 0 0 0 0 0 1 5 / 
Wu et al.2001 (37) 1 1 0 0 0 0 1 1 1 / 8 
Brown et al.1994 (38) 1 1 1 0 0 0 0 1 0 / 6 
Anderson et al.2007 
(39) 
1 1 1 1 1 0 0 1 1 / 8 
Victora et al.1987 (40) 1 1 0 0 0 0 0 0 1 8 / 
Cheng et al.2000 (41) 1 1 0 0 0 0 0 0 0 / 8 
Xu et al.2013 (42) 1 1 0 0 0 0 1 0 0 / 5 
Bradbury et al.2009 
(43) 
1 1 0 0 0 0 0 0 0 / 3 
De Jonge et al.2006 
(44) 
1 1 1 1 1 0 0 1 0 / 7 
Cohort studies            
Freedman et al.2007 
(45) 
1 1 1 1 0 1 0 1 0 8 7 
Zendehdel et al.2008 
(46) 
1 1 0 1 0 0 0 0 1 6 7 
Ishiguro et al.2009 (47) 1 1 1 1 0 1 0 0 1 8 / 
Bodelon et al.2011 (48) 1 1 1 0 0 0 0 0 1 5 7 
Ramus et al.2012 (49) 0 0 0 0 0 0 0 0 0 / 6 
Yates et al.2014 (50) 1 1 0 0 0 0 0 0 0 / 7 
Sikkema et al.2011 (51) 1 1 0 0 0 0 0 0 0 / 6 
Coleman et al.2012 
(52) 
1 1 0 0 1 0 0 1 0 / 9 
* For the adjusted variables, 1 represents adjusted that variable, 0 represents unadjusted that variable. Abbreviation: BMI=Body mass index; EAC=esophageal adenocarcinoma; 
ESCC= esophageal squamous cell carcinoma; NOS=Newcastle-Ottawa; SES=socio-economic status. 
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Supplementary Table 4: Quality assessment for each item of included case-control studies for risk ratio of 
esophageal squamous cell carcinoma and adenocarcinoma* 
Reference 
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
Total 
score Case 
definition 
Representative-
ness of cases 
Selection 
of controls 
Definition 
of 
controls 
Adjustment 
for 
alcohol/BMI
† 
Adjustment 
for 
diet/reflux‡ 
Ascertainment 
of the 
exposure 
Method of 
ascertainment 
Non-
response 
rate 
Smoking as 
main 
exposure 
Case-control studies for esophageal squamous cell carcinoma 
Steevens et al.2010 (1) 1 1 1 1 1 1 0 1 1 1 9 
Pandeya et al.2008 (2) 1 1 1 0 1 0 0 1 0 1 6 
Hashibe et al.2007 (3) 1 0 0 1 1 1 0 1 1 1 7 
Vioque et al.2008 (4) 1 1 0 1 1 1 1 1 1 1 9 
De Stefani et al.2005 (5) 1 1 0 1 1 1 1 1 1 0 8 
Lagergren et al.2000 (6) 1 1 1 0 1 1 1 1 1 1 9 
Zambon et al.2000 (7) 1 1 0 1 1 0 0 1 1 1 7 
Kabat et al.1993 (8) 1 0 0 1 1 0 1 1 0 1 6 
Gammon et al.1997 (9) 1 1 1 1 1 0 1 1 1 1 9 
Launoy et al.1997 (10) 1 1 0 1 1 0 1 1 0 1 7 
Tanaka et al.2010 (11) 1 1 0 1 1 0 0 1 0 1 6 
Szymanska et al.2011 (12) 1 1 0 1 1 1 1 1 1 1 9 
Castelletto et al.1994 (13) 1 1 0 1 1 0 1 1 0 1 7 
Bosetti et al.2000 (14) 1 1 0 1 1 0 1 1 0 1 7 
Lee et al.2005 (15) 1 1 0 1 1 1 0 1 0 1 7 
Venerito et al.2011 (16) 1 0 0 1 0 0 0 1 1 0 4 
Brown et al.1994 (17) 1 1 1 0 1 0 1 1 1 1 8 
Wang et al.2013 (18) 1 1 0 0 0 0 1 1 0 0 4 
Lindblad et al.2005 (19) 0 1 1 1 1 1 1 1 1 1 9 
Wang et al.2007 (20) 1 1 1 1 0 0 1 1 0 1 7 
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Shivappa et al.2015 (21) 1 0 0 1 0 0 0 1 0 0 3 
Nasrollahzadeh et al.2008 (22) 1 1 1 1 0 0 0 1 0 1 6 
Chen et al.2011 (23) 1 0 0 1 0 0 1 1 0 0 4 
Wu et al.2006 (24) 0 0 0 1 1 1 0 1 1 1 6 
De Stefani et al.1990 (25) 1 1 0 1 0 0 0 1 1 1 6 
Sewram et al.2003 (26) 1 1 0 1 0 0 1 1 1 0 6 
Vaughan et al.1995 (27) 1 1 1 1 1 1 0 1 1 1 9 
Gallus et al.2001 (28) 1 0 0 1 1 1 1 1 0 1 7 
Gao et al.2011 (29) 1 1 1 1 0 0 0 1 1 1 7 
Mota et al.2013 (30) 1 0 0 1 0 0 0 1 0 1 4 
Gledovic et al.2007 (31) 1 1 0 0 0 0 0 1 0 1 4 
Morita et al.2003 (32) 1 1 0 1 0 0 0 1 0 1 5 
Sharp et al.2001 (33) 1 1 1 1 0 1 0 1 1 1 8 
Kollarova et al.2013 (34) 1 1 0 1 1 0 0 1 0 1 6 
Lee et al.2009 (35) 1 1 0 1 1 0 0 1 0 1 6 
Lee et al.2012 (36) 1 1 0 1 0 0 0 1 1 0 5 
Victora et al.1987 (40) 1 1 0 1 1 1 1 1 0 1 8 
Case-control studies for esophageal adenocarcinoma 
Steevens et al.2010 (1) 1 1 1 1 1 0 0 1 1 1 8 
Wu et al.2001 (37) 1 1 1 1 0 0 1 1 1 1 8 
Brown et al.1994 (38) 1 1 1 0 0 0 0 1 1 1 6 
Pandeya et al.2008 (2) 1 1 1 0 1 1 0 1 0 1 7 
Hashibe et al.2007 (3) 1 0 0 1 1 0 1 1 1 1 7 
Anderson et al.2007 (39) 1 1 1 1 1 1 0 1 0 1 8 
Lagergren et al.2000 (6) 1 1 1 0 1 1 1 1 1 1 9 
Kabat et al.1993 (8) 1 1 0 1 0 0 0 1 1 1 6 
Gammon et al.1997 (9) 1 1 1 1 1 0 1 1 1 1 9 
Cheng et al.2000 (41) 1 1 1 1 0 0 1 1 1 1 8 
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* BMI=body mass index. 
† Adjustment for alcohol in studies for esophageal squamous cell carcinoma; adjustment for BMI in studies for esophageal adenocarcinoma. 
‡ Adjustment for diet in studies for esophageal squamous cell carcinoma; adjustment for reflux in studies for esophageal adenocarcinoma. 
Xu et al.2013 (42) 1 1 1 1 0 0 0 1 0 0 5 
Lindblad et al.2005 (19) 0 1 1 1 1 1 1 1 1 1 9 
Bradbury et al.2009 (43) 1 0 0 0 0 0 0 1 1 0 3 
Vaughan et al.1995 (27) 1 1 1 1 1 0 0 1 1 1 8 
De Jonge et al.2006 (44) 1 1 0 1 1 1 0 1 0 1 7 
Kollarova et al.2013 (34) 1 1 0 1 1 0 0 1 0 1 6 
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Supplementary Table 5: Quality assessment for each item of included cohort studies for risk ratio of esophageal 
squamous cell carcinoma and adenocarcinoma* 
* BMI=body mass index. 
† Adjustment for alcohol in studies for esophageal squamous cell carcinoma; adjustment for BMI in studies for esophageal adenocarcinoma. 
‡ Adjustment for diet in studies for esophageal squamous cell carcinoma; adjustment for reflux in studies for esophageal adenocarcinoma. 
  
Reference 
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
Total 
score 
Represent
ativeness 
of exposed 
cohort 
Selection of 
non-exposed 
cohort 
Ascertain
ment of the 
exposure 
Exclusion 
of 
outcome 
at 
baseline 
Adjustment 
for 
alcohol/BMI
† 
Adjustment 
for 
diet/reflux‡ 
Assessment 
of the 
outcome 
Follow-up for 
at least 10 
years 
Loss to 
follow-up 
<20% 
Smoking as 
main 
exposure 
Cohort studies for esophageal squamous cell carcinoma 
Freedman et al.2007 (45) 1 1 0 1 1 1 1 0 1 1 8 
Zendehdel et al.2008 (46) 0 1 0 1 0 0 1 1 1 1 6 
Ishiguro et al.2009 (47) 1 1 0 0 1 1 1 1 1 1 8 
Bodelon et al.2011 (48) 0 1 0 1 0 0 1 1 1 0 5 
Cohort studies for esophageal adenocarcinoma 
Freedman et al.2007 (45) 1 1 0 1 1 0 1 0 1 1 7 
Zendehdel et al.2008 (46) 0 1 0 1 1 0 1 1 1 1 7 
Ramus et al.2012 (49) 1 1 0 1 0 0 1 0 1 1 6 
Yates et al.2014 (50) 1 1 0 1 0 0 1 1 1 1 7 
Bodelon et al.2011 (48) 0 1 0 1 1 1 1 1 1 0 7 
Sikkema et al.2011 (51) 1 1 0 1 0 0 1 0 1 1 6 
Coleman et al.2012 (52) 1 1 1 1 0 1 1 1 1 1 9 
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Supplementary Table 6: Studies reporting the association between smoking cessation and risk of esophageal 
squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC) by cessation latency* 
Reference  Study design Histology  
Reference 
group 
No. of 
cases 
No. of 
controls/ 
cohort 
Risk ratios (95% confidence interval) by duration since quitting 
smoking  
Steevens et al.2010 (1) Case-control ESCC NS 107 3962 <10y:1.42 (0.62-3.23); 10-20y:1.28 (0.58-2.84); >20y:1.46 (0.63-
3.42) 
Pandeya  et al.2008 (2) Case-control ESCC NS 303 1580 ≤10y:2.39 (1.42-4.01); 10.01-20y:2.94 (1.77-4.89); 20.01-30y:2.20 
(1.32-3.66); >30y:1.44 (0.82-2.52) 
Hashibe et al.2007 (3) Case-control ESCC CS 192 1114 2-4y:0.32 (0.09-1.18); 5-9y:0.89 (0.4-1.96); 10-19y:0.30 (0.13-0.72);  
>20y:0.16 (0.07-0.39) 
Vioque et al.2008 (4) Case-control ESCC CS 160 455 <10y:0.44 (0.20 -0.96); ≥ 10y:0.49 (0.23-1.06) 
De Stefani et al.2005 (5) Case-control ESCC NS 200 400 1-9y:2.7(1.4-4.9); 10-19y:1.4(0.7-2.9); ≥20y,1.6(0.8-3.2) 
Lagergren et al.2000 (6) Case-control ESCC CS 167 820 <5y:0.456 (0.173-1.204); 5-9y: 0.433 (0.0.172-1.089); 10-19y:0.291 
(0.134-0.63);≥20y:0.155 (0.08-0.3) 
Zambon et al.2000 (7) Case-control ESCC NS 275 593 <5y:7.70 (3.21-18.49); 5-9y:4.10(1.84-9.10); ≥10y:1.54 (0.79-3.02) 
Kabat et al.1993 (8) Case-control ESCC CS 214 6772 in men: 1-5y:0.5 (0.3-1.0); 6-10y:0.4 (0.2-0.8); 11-20y:0.3 (0.2-0.6); 
>21y:0.2 (0.1-0.3); in women:1-10y: 0.4 (0.2- 0.9); >11y:0.3 (0.1-0.5) 
Gammon et al.1997 (9) Case-control ESCC NS 221 695 <11y:5.6(2.9-10.8); 11-20y:2.3(1.1-4.8); 21-30y:1.0(0.4-2.7); 
>30y:1.8(0.8-4.2) 
Launoy et al.1997 (10) Case-control ESCC CS 208 399 1-5y:1.43 (0.77-2.64); 6-10y:0.69 (0.33-1.46); ≥11y:0.51 (0.26-1.00) 
Tanaka et al.2010 (11) Case-control ESCC NS 742 820 <1y:21.8 (5.7- 82.9); 1-2y:3.7 (1.2‒ 11.5); 3-9y:4.6 (2.1- 10.1);  
>10y:2.8 (1.4‒ 5.4) 
Szymanska et al.2011 
(12) 
Case-control ESCC CS 171 1707 2-4y:0.42 (0.18-0.99); 5-9y:0.32 (0.13-0.81); 10-19y:0.45(0.23-0.89); 
≥20y:0.23 (0.11-0.49) 
Castelletto et al.1994 
(13) 
Case-control ESCC CS 131 262 2-7y: 1.5(0.6-3.3); 8-19y:0.5 (0.2-1.2); ≥20y:1.3(0.5-3.3) 
Bosetti et al.2000 (14) Case-control ESCC CS 404 1070 1-2y: 1.37 (0.64-2.96); 3-5y:1.10 (0.60-2.04); 6-9y:0.58 (0.31-1.07); 
10-14y:0.31 (0.17-0.56); ≥15y:0.31 (0.20-0.49) 
Lee et al.2005 (15) Case-control ESCC CS 513 818 1-5y:1.4 (0.8-2.3); 6-10y:0.4 (0.2-0.9); >10y:0.5 (0.3-0.9) 
Victora et al.1987 (40) Case-control ESCC CS 171 342 all:1-7y:1.00(0.72-1.39); 8-19y:0.39(0.20-0.78); >20y:0.48(0.25-
0.90); in men:1-7y:1.01(0.71-1.42); 8-19y:0.38(0.18-
0.79);>20y:0.45(0.23-0.88); in women: 1-7y:0.94(0.32-2.83); 8-
19y:0.40(0.07-2.39); 
>20y:0.94(0.12-7.27) 
Freedman et al.2007 
(45) 
Cohort ESCC NS 97 474606 1-4y:10.30 (3.88 -27.35); 5-9y:6.70 (2.57-17.47); >10y:3.24(1.40-
7.49) 
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Zendehdel et al.2008 
(46) 
Cohort ESCC NS 236 336381 <5y:1.0 (0.3-3.5); ≥5y:0.8 (0.3-2.1) 
Steevens et al.2010 (1) Case-control EAC NS 145 3962 <10y:1.66 (0.95 -2.91); 10-20y:1.42 (0.80 -2.51); >20y:1.32 (0.70-
2.47) 
Wu et al.2001 (37) Case-control EAC NS 222 1356 1-5y:2.17(1.2-3.9); 6-10y:1.09(0.5-2.3); 11-19y:1.74(1.1-2.9); 
 >20y:1.33(0.8-2.1) 
Brown et al.1994 (38) Case-control EAC NS 174 750  1-9y:2.0 (1.0-4.1); 10-19y:2.4 (1.2-4.9); 20-29y:2.2 (1.0-4.7);>30y: 
3.1 (1.5-6.6) 
Pandeya et al.2008 (2) Case-control EAC NS 367 1580 ≤10y:1.58 (1.00-2.51); 10.01-20y:1.99 (1.29-3.06); 20.01-30y: 
1.26(0.79-1.99);>30y:1.06 (0.65-1.73) 
Hashibe et al.2007 (3) Case-control EAC CS 35 1114 2-4y:1.38 (0.26-7.30); 5-9y:1.19 (0.24-5.81); ); 10-19y:0.60 (0.12-
3.03); >20y:1.19 (0.39-3.61) 
Anderson et al.2007 (39) Case-control EAC NS 227 260 < 26y:4.89 (2.74-8.71); 26-41y:2.51 (1.30 - 4.83); > 41y:1.40 (0.74- 
2.66) 
Lagergren et al.2000 (6) Case-control EAC CS 189 820 <5y:1.872(0.728-4.848); 5-9y: 0.864 (0.307-2.426); 10-19y: 1.012 
(0.495-2.068); ≥20y: 0.949 (0.526-1.712) 
Kabat et al.1993 (8) Case-control EAC CS 194 6772 in men:1-5y:0.5 (0.2-1.1);6-10y:1.1 (0.6-1.9);11-20y:1.2 (0.8-1.9); 
>21y:0.5 (0.3-0.9); in women:1-10y:0.3 (0.1-1.7); >11y:0.3 (0.1-1.7) 
Gammon et al.1997 (9) Case-control EAC NS 293 695 <11y:2.7(1.6-4.4); 11-20y:2.3(1.4-3.8); 21-30y:1.9(1.1-3.2);  
>30y:1.2(0.7-2.2) 
Freedman et al.2007 
(45) 
Cohort EAC NS 205 474606 1-4y:2.21 (0.99-4.93); 5-9y:4.04 (2.33-7.00); >10y:2.67 (1.72 -4.16) 
Zendehdel et al.2008 
(46) 
Cohort EAC NS 130 336381 <5y:2.1 (0.9-4.9); ≥5y:0.8 (0.3-1.8) 
Ramus et al.2012 (49) Cohort EAC NS 73 956 all: <10y:1.98 (0.9-4.4); ≥10y:3.22 (1.6-6.5); in men: <10y:2.52 
(0.94-6.8); ≥10y:4.15 (1.7-10.1); in women: <10y:1.14 (0.24-5.5); ≥
10y:1.8 (0.5-6.8) 
* CS=current smoker; NS=non-smoker.    
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Supplementary Table 7: Smoking cessation and the risk of esophageal squamous cell carcinoma and esophageal 
adenocarcinoma by cessation latency 
Type of analysis 
Esophageal squamous cell carcinoma  Esophageal adenocarcinoma 
Smoking status RR (95% CI) 
Studies 
(n) 
PHeterogeneity* I
2
(%)  Smoking status RR (95% CI) 
Studies 
(n) 
PHeterogeneity* I
2
(%) 
Pooled with all data available†   
 Current smokers Reference     Current smokers Reference    
 Quit<5 years ago 0.96(0.73-1.25) 12 .04 45.5  Quit<5 years ago 0.81(0.52-1.26) 5 .26 23.5 
 Quit 5-9 years ago 0.59(0.47-0.75) 10 .44 0.0  Quit 5-9 years ago 0.87(0.58-1.30) 5 .23 28.2 
 Quit 10-20 years ago 0.42(0.34-0.51) 11 .62 0.0  Quit 10-20 years ago 0.95(0.78-1.15) 8 .47 0.0 
 Quit >20 years ago 0.34(0.25-0.47) 11 .001 65.8  Quit >20 years ago 0.72(0.52-1.01) 8 .003 67.0 
 Non-smokers 0.22(0.18-0.28) 15 .002 59.3  Non-smokers 0.40(0.33-0.48) 12 .15 29.9 
Pooled with data from those studies reporting all quit-smoking duration categories  
 Current smokers Reference     Current smokers Reference    
 Quit <5 years ago 0.58(0.34-0.99) 5 .05 58.3  Quit <5 years ago 0.90(0.51-1.57) 4 .21 34.6 
 Quit 5-9 years ago 0.51(0.36-0.71) 5 .46 0.0  Quit 5-9 years ago 0.78(0.45-1.36) 4 .19 36.7 
 Quit 10-20 years ago 0.33(0.24-0.44) 5 .89 0.0  Quit 10-20 years ago 0.90(0.62-1.30) 4 .25 27.3 
 Quit >20 years ago 0.22(0.17-0.29) 5 .41 0.0  Quit >20 years ago 0.64(0.43-0.97) 4 .17 40.6 
 Non-smokers 0.18(0.13-0.24) 5 .21 32.5  Non-smokers 0.44(0.33-0.57) 4 .54 0.0 
*P values from two-sided Cochran’s Q test. CI=confidence interval; RR=risk ratio. 
†One study (Tanaka et al.2010) reported data for 0-1 and 1-2 years of smoking cessation, we pooled them into <5 years group and we also pooled 3-9 years group into 5-9 years 
group. Two studies (Castelletto et al.1994 and Victora at al.1987)  reported data for 1-7 years and they were reclassified into <5 years group, and data of 8-19 years and 10-14 years 
were reclassified into 10-20 years. And one study (Bosetti et al.2000) had >15 years group which was put into >20 years group in our analysis. 
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Supplementary Table 8: Tobacco smoking status and risk of esophageal adenocarcinoma, using non-smokers as 
reference 
Study characteristics 
Former smokers   Current smokers 
Risk ratio  
(95% CI) 
Studies 
(n) 
Pheterogeneity* I
2 
(%)† 
 Risk ratio  
(95% CI) 
Studies 
(n) 
Pheterogeneity* I
2 
(%)† 
Overall 1.66 (1.48-1.85) 23 .30 11.6  2.35 (2.04-2.69) 23 .13 26.0 
Study design          
Case-control 1.65 (1.47-1.86) 17 .39 5.1   2.24 (1.91-2.64) 17 .09 33.2 
Cohort 1.70 (1.23-2.35) 6 .18 34.9   2.65 (2.03-3.46) 6 .53 0.0 
Publication year          
≤1999 1.92 (1.55-2.38) 5 .41 0.0   2.31 (1.84-2.89) 5 .58 0.0 
2000-2009 1.62 (1.35-1.96) 11 .10 37.3  2.48 (1.94-3.18) 11 .01 57.0 
 ≥2010 1.55 (1.23-1.96) 7 .84 0.0   1.99 (1.53-2.58) 7 .87 0.0 
Geographic origin          
North America 1.87 (1.62-2.16) 10 .42 2.5  2.52 (2.14-2.96) 10 .82 0.0 
Europe 1.48 (1.25-1.76) 12 .47 0.0  2.16 (1.67-2.79) 12 .04 46.1 
Oceania 1.46 (1.05-2.02) 1 1.00 0.0  2.51 (1.66-3.82) 1 1.00 0.0 
Sex‡          
Men 1.59 (0.96-2.64) 4 .02 71.3   2.12 (1.46-3.07) 4 .06 58.8 
Women 1.36 (0.90-2.07) 4 .58 0.0  2.15 (1.27-3.65) 4 .34 9.9 
Unspecified 1.65 (1.46-1.86) 16 .39 5.5   2.37 (2.03-2.77) 16 .07 34.8 
Response rate          
≥80%  1.48 (1.23-1.79) 8 .71 0.0  2.08 (1.67-2.60) 8 .28 18.9 
<80% 1.83 (1.51-2.20) 10 .10 38.9  2.48 (1.98-3.09) 10 .11 37.2 
Unknown  1.61 (1.23-2.11) 5 .58 0.0   2.26 (1.72-2.98) 5 .39 2.4 
Smoking exposure          
Main exposure 1.67 (1.46-1.91) 20 .17 23.2   2.33 (1.98-2.73) 20 .06 35.5 
Confounder  1.69 (1.31-2.20) 3 .94 0.0   2.21 (1.60-3.06) 3 .89 0.0 
Tobacco types          
Cigarettes  1.73 (1.42-2.10) 11 .14 32.6  2.29 (1.93-2.72) 11 .50 0.0 
16 
 
Unspecified 1.62 (1.40-1.88) 12 .56 0.0  2.35 (1.87-2.95) 12 .04 46.2 
Study quality          
Low  (score<7) 1.85 (1.51-2.27) 7 .49 0.0   2.24 (1.77-2.83) 7 .62 0.0 
High (score≥7) 1.61 (1.41-1.85) 16 .25 17.8   2.34 (1.95-2.79) 16 .05 40.7 
 
Adjusted variables          
Body mass index          
Yes 1.71 (1.45-2.03) 13 .18 25.8  2.43 (1.91-3.11) 12 .01 53.5 
No 1.64 (1.39-1.92) 10 .48 0.0  2.27 (1.92-2.69) 11 .81 0.0 
Gastroesophageal 
reflux 
         
Yes 1.53 (1.24-1.89) 6 .37 8.0   1.97 (1.50-2.58) 6 .20 31.0  
No 1.73 (1.51-1.98) 17 .31 12.5   2.46 (2.12-2.84) 17 .33 10.6 
Socio- economy          
Yes 1.77 (1.55-2.01) 13 .66 0.0  2.50 (2.08-3.00) 13 .17 27.4 
No 1.52 (1.21-1.90) 10 .14 33.0   2.04 (1.69-2.46) 10 .35 10.1 
Place of residence          
Yes 1.67 (1.42-1.97) 9 .88 0.0  2.74 (2.28-3.30) 9 .58 0.0 
No 1.68 (1.40-2.01) 14 .07 38.5   2.04 (1.72-2.41) 14 .24 20.0 
Case-control study          
Study design          
Population-based 1.59 (1.37-1.84) 11 .23 22.8  2.12 (1.73-2.60) 11 .04 48.1 
Hospital-based 1.90 (1.48-2.44) 6 .81 0.0  2.62 (1.99-3.47) 6 .76 0.0 
Cases recruitment          
Incident 1.93 (1.64-2.28) 10 .75 0.0   2.16 (1.79-2.61) 10 .62 0.0 
Prevalent  1.41 (1.20-1.66) 7 .71 0.0  2.11 (1.70-2.61) 7 .17 33.9 
Unknown  1.72 (1.06-2.81) 1 1.00 0.0   4.84 (2.72-8.61) 1 1.00 0.0 
Cohort study          
Study design          
Population-based  1.96 (1.14-3.35) 3 .10 57.5  2.92 (1.86-4.59) 3 .34 6.6 
BE-based 1.51 (0.92-2.49) 2 .56 0.0  2.07 (1.26-3.39) 2 .43 0.0 
Occupation-based 1.20 (0.60-2.40) 1 1.00 0.0  2.90 (1.80-4.80) 1 1.00 0.0 
Follow-up time          
17 
 
<10 years 1.98 (1.22-3.22) 3 .15 47.0   2.61 (1.62-4.20) 3 .21 36.5 
≥10 years 1.35 (0.91-2.02) 3 .68 0.0   2.55 (1.70-3.83) 3 .63 0.0 
Outcome assessment          
Record linkage 1.65 (1.13-2.41) 5 .11 47.7  2.65 (2.00-3.49) 5 .39 3.2 
Self-reported 1.92 (0.79-4.65) 1 1.00 0.0   2.49 (0.52-11.98) 1 1.00 0.0 
 
* P-values from two-sided Cochran’s Q test. CI=confidence interval. 
† I
2
 statistics indicating the percentage of variation across studies that is due to heterogeneity.  
‡ One study (Ramus et al.2012) reported risk ratio for men and women separately and combined; one study (Kabat et al.1993) reported risk ratio for men and women separately.  
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Supplementary Figures 
 
 
Supplementary Figure 1: Forest plot of risk ratio of esophageal squamous cell carcinoma among 
current smokers with non-smokers as reference, stratified by study design. The diamonds 
represent the effect sizes for the studies combined, the squares represent the effect sizes of individual 
studies and the weights given to the studies, and the error bars represent the corresponding 95% 
confidence intervals. CI=confidence interval. 
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Supplementary Figure 2: Forest plot of risk ratio of esophageal squamous cell carcinoma among 
former smokers with current smokers as reference, stratified by smoking cessation years. The 
diamonds represent the effect sizes for the studies combined, the squares represent the effect sizes of 
individual studies and the weights given to the studies, and the error bars represent the corresponding 95% 
confidence intervals. CI=confidence interval. 
20 
 
 
 
Supplementary Figure 3: Sensitivity analysis for risk ratio of esophageal squamous cell 
carcinoma in former smokers by one-study removed strategy. The diamonds represent the effect 
sizes for the studies combined, the squares represent the effect sizes of individual studies and the 
weights given to the studies, and the error bars represent the corresponding 95% confidence intervals. 
CI=confidence interval. 
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Supplementary Figure 4: Sensitivity analysis for risk ratio of esophageal squamous cell 
carcinoma in current smokers by one-study removed strategy. The diamonds represent the 
effect sizes for the studies combined, the squares represent the effect sizes of individual studies and the 
weights given to the studies, and the error bars represent the corresponding 95% confidence intervals. 
CI=confidence interval. 
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Supplementary Figure 5: Forest plot of risk ratio of esophageal adenocarcinoma among current 
smokers with non-smokers as reference, stratified by study design. The diamonds represent the 
effect sizes for the studies combined, the squares represent the effect sizes of individual studies and the 
weights given to the studies, and the error bars represent the corresponding 95% confidence intervals. 
CI=confidence interval. 
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Supplementary Figure 6: Forest plot of risk ratio of esophageal adenocarcinoma among former 
smokers with current smokers as reference, stratified by smoking cessation years. The diamonds 
represent the effect sizes for the studies combined, the squares represent the effect sizes of individual 
studies and the weights given to the studies, and the error bars represent the corresponding 95% 
confidence intervals. CI=confidence interval. 
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Supplementary Figure 7: Funnel plots and Begg’s and Egger’s tests detecting publication bias.  A) 
Risk of esophageal squamous cell carcinoma in former smokers; B) Risk of esophageal squamous cell 
carcinoma in current smokers. C) Risk of esophageal adenocarcinoma in former smokers. D) Risk of 
esophageal adenocarcinoma in current smokers. All P values are from two-sided tests. 
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Table 1 Tobacco smoking status and risk of esophageal squamous cell carcinoma, using non-smokers as the reference. 
Study characteristics 
Former smokers  Current smokers 
Risk Ratio (95% CI) Studies (n) Pheterogeneity* I
2
(%)†  Risk Ratio (95% CI) Studies (n) Pheterogeneity* I
2
(%)† 
Overall 2.05 (1.71-2.45) 41 <.001 69.6  4.18 (3.42-5.12) 41 <.001 85.0 
Study design          
Case-control 2.01 (1.67-2.43) 37 <.001 70.4  3.81 (3.06-4.74) 37 <.001 85.6 
Cohort 2.50 (1.29-4.85) 4 .03 66.2  6.95 (4.17-11.57) 4 .10 52.9 
Publication year          
≤1999 1.98 (1.54-2.54) 8 .26 21.7  5.07 (3.35-7.68) 8 <.001 75.3 
2000-2009 1.85 (1.47-2.34) 21 <.001 67.8  3.62 (2.83-4.64) 21 <.001 79.5 
≥2010 2.57 (1.69-3.91) 12 <.001 78.7  4.29 (2.54-7.24) 12 <.001 91.8 
Geographic origin          
North America 2.45 (1.83-3.27) 7 .31 16.3  5.75 (3.56-9.26) 7 .002 70.7 
Europe 1.75 (1.15-2.65) 14 <.001 79.3  4.57 (3.19-6.54) 14 <.001 81.5 
Oceania 2.18 (1.51-3.17) 1 1.00 0.0  4.58 (2.99-7.02) 1 1.00 0.0 
Asia 2.47 (1.78-3.44) 12 <.001 72.6  2.82 (1.81-4.39) 12 <.001 91.5 
South America 1.67 (1.37-2.04) 7 .67 0.0  2.91 (2.41-3.50) 7 .47 0.0 
Sex‡          
Men 2.00 (1.43-2.80) 10 .01 57.2  3.77 (2.29-6.20) 10 <.001 85.7 
Women 1.34 (0.71-2.53) 6 .006 69.1  3.85 (2.20-6.74) 6 .003 72.2 
Unspecified 2.26 (1.86-2.76) 29 <.001 66.9  3.94 (3.12-4.99) 29 <.001 84.0 
Response rate          
≥80%  1.92 (1.56-2.36) 15 .05 40.6  4.21 (2.74-6.47) 15 <.001 90.4 
<80% 2.42 (1.70-3.45) 10 <.001 70.1  4.80 (3.09-7.43) 10 <.001 83.2 
Unknown  1.95 (1.36-2.78) 16 <.001 79.3  3.51 (2.69-4.60) 16 <.001 76.9 
Smoking exposure          
Main exposure 1.88 (1.57-2.24) 33 <.001 60.6  3.97 (3.17-4.96) 33 <.001 81.3 
Confounder  3.08 (1.90-4.98) 8 <.001 81.2  4.35 (2.44-7.76) 8 <.001 92.7 
Tobacco types          
Cigarettes  2.38 (1.58-3.60) 15 <.001 82.8  4.02 (3.07-5.28) 15 <.001 72.7 
Unspecified 1.94 (1.66-2.26) 26 .01 41.9  3.96 (2.94-5.33) 26 <.001 88.4 
Study quality          
Low (score<7) 2.16 (1.63-2.86) 19 <.001 74.8  3.60 (2.65-4.90) 19 <.001 87.0 
High (score≥7) 1.97 (1.57-2.48) 22 <.001 64.7  4.45 (3.31-5.99) 22 <.001 83.5 
Adjusted variables          
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Alcohol use          
Yes 2.09 (1.72-2.54) 22 .02 42.3  4.59 (3.67-5.74) 19 <.001 60.1 
No 2.05 (1.52-2.76) 19 <.001 81.1  3.54 (2.56-4.88) 21 <.001 90.6 
Dietary factors          
Yes 1.76 (1.20-2.58) 12 <.001 71.0  4.42 (3.11-6.28) 11 .001 67.6 
No 2.17 (1.78-2.66) 29 <.001 69.4  3.91 (3.04-5.03) 30 <.001 87.6 
Socio-economy          
Yes 2.07 (1.73-2.49) 18 .11 30.0  4.19 (3.20-5.48) 16 <.001 70.9 
No 2.04 (1.54-2.70) 23 <.001 79.4  3.93 (2.93-5.27) 25 <.001 88.8 
Place of residence          
Yes 2.02 (1.67-2.45) 20 .01 46.5  3.78 (2.85-5.01) 19 <.001 79.3 
No 2.09 (1.55-2.82) 21 <.001 78.9  4.26 (3.14-5.79) 22 <.001 88.1 
Case-control study          
Study design          
Population-based 1.66 (1.19-2.30) 11 <.001 71.3  3.23 (1.98-5.29) 11 <.001 90.4 
Hospital-based 2.21 (1.77-2.75) 26 <.001 68.0  4.10 (3.26-5.15) 26 <.001 80.6 
Cases recruitment          
Incident 2.20 (1.78-2.73) 28 <.001 73.4  4.21 (3.28-5.40) 28 <.001 86.1 
Prevalent 1.49 (1.01-2.19) 7 .08 47.3  2.90 (1.77-4.75) 7 <.001 83.1 
Unknown 1.32 (0.73-2.38) 2 .60 0.0  2.11 (0.58-7.61) 2 .04 77.4 
Source of controls          
Unrelated 2.07 (1.71-2.51) 35 <.001 70.1  4.05 (3.28-5.01) 35 <.001 82.9 
Neighborhood 1.36 (0.98-1.89) 2 .95 0.0  1.30 (0.96-1.77) 2 .30 5.3 
Cohort study          
Study design          
Population-based 3.46 (2.26-5.31) 3 .79 0.0  6.98 (3.19-15.28) 3 .06 65.6 
Occupation-based 0.90 (0.40-2.00) 1 1.00 0.0  7.60 (4.50-12.70) 1 1.00 0.0 
Follow-up time          
<10 years 4.35 (1.95-9.72) 1 1.00 0.0  9.27 (4.04-21.29) 1 1.00 0.0 
≥10 years 2.08 (0.92-4.70) 3 .03 70.4  6.51 (3.42-12.42) 3 .06 64.0 
Outcome assessment          
Record linkage 2.37 (0.98-5.77) 3 .01 77.2  6.16 (3.56-10.66) 3 .10 56.2 
Self-reported 2.93 (1.18-7.32) 1 1.00 0.0  12.67 (4.55-35.28) 1 1.00 0.0 
* P-values from two-sided Cochran’s Q test. Abbreviation: CI: confidence intervals. 
† I
2 
statistics indicating the percentage of variation across studies that is due to heterogeneity. 
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‡Two studies (Stefani et al.1990 and Victora et al.2007) reported risk ratio for men and women separately and combined; one study (Kabat et al.1993) 
reported risk ratio for men and women separately.  
 
  
 
     14979 records identified 
                 7824 from Medline 
                 3639 from Embase 
                 3204 from Web of Science  
                 309 from Cochrane Library 
 
30 additional records identified 
through clinicaltriavls.gov 
11029 records screened after duplicates removed 
 
1819 potentially relevant articles identified for 
further full-text review  
9210 records excluded on the basis of 
screening of title or abstracts 
 
 
 
205 articles met the inclusion 
criteria 
1614 articles excluded on the basis of first round of full-  
          text review 
           973 included only relevant exposure (smoking) or     
                    outcome, not both 
           311 were without original data (review, meeting      
                    abstracts, protocol, books, guidelines, etc.) 
           101 were lab works 
           83 were incidence rate studies 
           77 were duplicates 
           56 were not in English  
           13 were case reports 
 
52 articles included in the  
meta-analysis  
                41 articles for ESCC 
                23 articles for EAC   
 
23 articles identified from reference lists  
176 articles excluded on the basis of second round of full- 
        text review 
         53 lacked histology information 
         39 used data from same population of included studies 
         31 lacked former smoker data 
         25 were duplicates 
         8 were pooled analysis without original data  
         5 were not tobacco smoking related 
         4 were not specific esophageal cancer   
         4 used outcome of mortality 
         4 had data unavailable or could not be extracted 
         2 were letters to editors 
         1 used outcome of second primary cancer  
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